USE OF AN FGF-21 COMPOUND AND A GLP-1 COMPOUND FOR THE TREATMENT OF OBESITY
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention.
-
Citations
37 Claims
-
1-15. -15. (canceled)
-
16. A method of treating obesity comprising administering an FGF-21 compound in combination with a GLP-1 compound, wherein the FGF-21 compound is an FGF-21 analog selected from the group consisting of Cys118-Cys134-FGF-21 (SEQ ID NO:
- 9), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO;
10), Cys21-Cys33-Ala167-FGF-21 (SEQ ID NO;
11), Cys26-Cys122-Ala167-FGF-21 (SEQ ID NO;
12), and Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO;
13). - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
- 9), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO;
-
27. A method of lowering body weight comprising administering an FGF-21 compound in combination with a GLP-1 compound, wherein the FGF-21 compound is an FGF-21 analog selected from the group consisting of Cys118-Cys134-FGF-21 (SEQ ID NO:
- 9), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO;
10), Cys21-Cys33-Ala167-FGF-21 (SEQ ID NO;
11), Cys26-Cys122-Ala167-FGF-21 (SEQ ID NO;
12), and Cys118-Cys134-Ala121-Ala167-FGF-21 (SEQ ID NO;
13). - View Dependent Claims (28, 29, 30, 31, 32, 33, 34, 35, 36, 37)
- 9), Cys118-Cys134-Ala167-FGF-21 (SEQ ID NO;
Specification